<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265770</url>
  </required_header>
  <id_info>
    <org_study_id>SIOP Ependymoma II (ET-13-002)</org_study_id>
    <secondary_id>2013-002766-39</secondary_id>
    <secondary_id>VHP358</secondary_id>
    <nct_id>NCT02265770</nct_id>
  </id_info>
  <brief_title>An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma</brief_title>
  <acronym>SIOP-EP-II</acronym>
  <official_title>An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this project is to improve the outcome of patients diagnosed with&#xD;
      ependymoma by improving and harmonising the staging and the standard of care of this patient&#xD;
      population and to improve the investigators understanding of the underlying biology thereby&#xD;
      informing future treatment.&#xD;
&#xD;
      The program will evaluate new strategies for diagnosis (centralized reviews of pathology and&#xD;
      imaging) and new therapeutic strategies in order to develop treatment recommendations.&#xD;
&#xD;
      Patients will be stratified into different treatment subgroups according to their age, the&#xD;
      tumour location and the outcome of the initial surgery. Each subgroup will be studied in a&#xD;
      specific randomised study to evaluate the proposed therapeutic strategies.&#xD;
&#xD;
      Stratum 1:&#xD;
&#xD;
      The aim of the stratum 1 is to evaluate the clinical impact of 16-week chemotherapy regimen&#xD;
      with VEC-CDDP following surgical resection and conformal radiotherapy in terms of progression&#xD;
      free survival in patients who are &gt; 12 months and &lt; 22 years at diagnosis, with completely&#xD;
      removed intra cranial Ependymoma.&#xD;
&#xD;
      Stratum 2:&#xD;
&#xD;
      This stratum is designed as a phase II trial for patients who are &gt; 12 months and &lt; 22 years&#xD;
      at diagnosis, with residual disease to investigate the possible activity of HD-MTX by giving&#xD;
      to all patients the benefit of VEC chemotherapy whilst randomising half of patients to&#xD;
      receive additional HD-MTX.&#xD;
&#xD;
      Patients will receive conformal radiotherapy (cRT). For patients who remain with a residual&#xD;
      inoperable disease after induction chemotherapy and cRT, an 8 Gy boost of radiotherapy to the&#xD;
      residual tumour will be delivered immediately after the end of the cRT.&#xD;
&#xD;
      Stratum 3 This stratum is designed as a phase II trial to evaluate the benefit of&#xD;
      postoperative dose intense chemotherapy administered alone or in combination with valproate&#xD;
      in children &lt;12 months of age or those not eligible to receive radiotherapy .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Ependymoma Program is a comprehensive program to improve the accuracy of the primary&#xD;
      diagnosis of ependymoma and explore different therapeutic strategies in children, adolescents&#xD;
      and young adults, accordingly. This program is opened to all patients diagnosed with&#xD;
      ependymoma below the age of 22 years.&#xD;
&#xD;
      It will include a centralised review of pre and post-operative imaging to assess the&#xD;
      completeness of the resection.&#xD;
&#xD;
      It will also include a central review of pathology to confirm the histological diagnosis. The&#xD;
      biological markers 1q gain, Tenascin C status, NELL2 and LAMA2, RELA-fusion and molecular&#xD;
      subgroup by methylation array will be prospectively assessed for prospective evaluation of&#xD;
      disease subgroups. Further biological evaluations will be coordinated within the linked&#xD;
      BIOMECA study.&#xD;
&#xD;
      After surgery and central review of imaging and pathology, patients will be offered the&#xD;
      opportunity to undergo second look surgery, if possible. Patients will be enrolled in one of&#xD;
      3 different strata according to the outcome of the initial surgical resection (residual&#xD;
      disease vs no residual disease), their age or eligibility / suitability to receive&#xD;
      radiotherapy. These 3 different strata correspond to 3 therapeutic strategies according to&#xD;
      the patient status.&#xD;
&#xD;
        1. Stratum 1 is designed as a randomised phase III study for patients who have had a&#xD;
           complete resection, with no measurable residual disease (as confirmed by centrally&#xD;
           reviewed MRI) and are &gt; 12 months and &lt; 22 years at diagnosis. Those patients will be&#xD;
           randomised to receive conformal radiotherapy followed by either 16 weeks of chemotherapy&#xD;
           with VEC-CDDP, or observation.&#xD;
&#xD;
        2. Stratum 2 is designed as a randomised phase II study for patients who have inoperable&#xD;
           measurable residual disease and who are &gt; 12 months and &lt; 22 years at diagnosis. Those&#xD;
           patients will be randomised to two different treatment schedules of chemotherapy either&#xD;
           with VEC or VEC+ high dose methotrexate (VEC +HD-MTX). After completion of the frontline&#xD;
           chemotherapy, patients will be assessed for response (MRI) and will receive second look&#xD;
           surgery when feasible. For those patients who remain unresectable with residual disease&#xD;
           despite frontline chemotherapy and for whom second line surgery is not feasible, there&#xD;
           will be a study of the safety of a radiotherapy boost of 8 Gy that will be administered&#xD;
           to the residual tumour immediately after the completion of the conformal radiotherapy.&#xD;
           Patients without evidence of residual disease after the chemotherapy and/or a second&#xD;
           look surgery are not eligible for radiotherapy boost. All patients who have not shown&#xD;
           progression under chemotherapy will receive, as maintenance therapy, a 16 week course of&#xD;
           VEC -CDDP following completion of radiotherapy.&#xD;
&#xD;
        3. Stratum 3 is designed as a randomised phase II chemotherapy study in children &lt;12 months&#xD;
           of age or those not eligible to receive radiotherapy. These patients will be randomised&#xD;
           to receive a dose dense chemotherapy alternating myelosuppressive and relatively&#xD;
           non-myelosuppressive drugs at 2 weekly intervals, with or without, the addition of the&#xD;
           histone deacetylase inhibitor, valproate.&#xD;
&#xD;
      Registry: Patients that do not fulfil the inclusion criteria of one of the interventional&#xD;
      strata will be enrolled and followed up via an observational study which will be analysed&#xD;
      descriptively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2015</start_date>
  <completion_date type="Anticipated">August 2031</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gross Total Resection rate</measure>
    <time_frame>3 years</time_frame>
    <description>Overall program, depends on the stratum (from 0.5 years to 3 years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 4.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment responders</measure>
    <time_frame>15 months after final patient inclusion</time_frame>
    <description>Objective response to chemotherapy is measured based on SIOP-E Neuro Imaging guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants undergoing a second-look surgery</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years after the final patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Survival</measure>
    <time_frame>from date of randomization up to 5 years after the end of treatment</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of neuropsychological morbidity</measure>
    <time_frame>from date of randomization up to 5 years after the end of treatment</time_frame>
    <description>Scores: evaluation of processing speed (WPPSI-III, WISC-IV, WAIS-IV), verbal skills (WPPSI-III, WISC-IV, WAIS-IV), fluid intelligence (WPPSI-III / Ravens, WISC-IV / Ravens, WAIS-IV / Ravens), working memory (K-ABC / Children's Memory Scale, WISC-IV, WAIS-IV), visuo-spatial abilities (Beery-Buktenica Developmental Test of Visual-Motor Integration/Wide Range Assessment of Visual Motor Abilities - WRAVMA), regarding ability (as to national policy/WIAT-II) and motoric speed (Perdue Pegboard)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of neuroendocrine morbidity</measure>
    <time_frame>from date of randomization up to 5 years after the end of treatment</time_frame>
    <description>Weight, height and head circumference, Tanner age, early and delayed pubertal onset, blood sample analysis (evaluation of TSH, fT4, LH and FSH, oestradiol, testosterone, insulin-like growth factor 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>from date of randomization up to 5 years after the end of treatment</time_frame>
    <description>Determination of short and long term safety and toxicity of frontline chemotherapy based on proportion of patients experiencing toxicity grade 3 to 4 (adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy-free survival rate</measure>
    <time_frame>from date of randomization until the date of first documented progression or date of death from any cause, or radiotherapy intervention, whichever came first, up to 2.5 years after the final patient inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Childhood Ependymoma</condition>
  <arm_group>
    <arm_group_label>Stratum 1 arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conformal radiotherapy followed by 16 weeks of VEC + CDDP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 1 arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conformal radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2 arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEC + HD-MTX followed by conformal radiotherapy +/- boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2 arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VEC followed by conformal radiotherapy +/- boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 3 arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy + Valproate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 3 arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>16 weeks of VEC + CDDP</intervention_name>
    <description>Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.</description>
    <arm_group_label>Stratum 1 arm A</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEC + HD-MTX</intervention_name>
    <description>Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.</description>
    <arm_group_label>Stratum 2 arm A</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy + Valproate</intervention_name>
    <description>Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.&#xD;
Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses.</description>
    <arm_group_label>Stratum 3 arm A</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Carboplatin</other_name>
    <other_name>Methotrexate</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>Valproate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conformal radiotherapy</intervention_name>
    <description>Conformal radiotherapy: 59.4Gy (children &lt;18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.</description>
    <arm_group_label>Stratum 1 arm A</arm_group_label>
    <arm_group_label>Stratum 1 arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEC</intervention_name>
    <description>D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes</description>
    <arm_group_label>Stratum 2 arm B</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.</description>
    <arm_group_label>Stratum 3 arm B</arm_group_label>
    <other_name>Vincristine</other_name>
    <other_name>Carboplatin</other_name>
    <other_name>Methotrexate</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conformal radiotherapy +/- boost</intervention_name>
    <description>Conformal radiotherapy: 59.4Gy (children &lt;18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.&#xD;
In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions</description>
    <arm_group_label>Stratum 2 arm A</arm_group_label>
    <arm_group_label>Stratum 2 arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        After Initial surgery, patients will be enrolled in one of 3 different interventional&#xD;
        strata where they will be offered a set of therapeutic interventions based on the outcome&#xD;
        of the intervention (no measurable residue vs residual inoperable disease), their age&#xD;
        and/or their eligibility /suitability to receive radiotherapy.&#xD;
&#xD;
        Patients with centrally and histologically confirmed intracranial ependymoma meeting the&#xD;
        following criteria will be enrolled into one of interventional stratum:&#xD;
&#xD;
          -  Age &lt; 22 years old at diagnosis&#xD;
&#xD;
          -  Newly diagnosed with an ependymoma WHO grade II and III, including ependymoma&#xD;
             variants: papillary, clear-cell and tanycytic, RELA fusion positive or anaplastic&#xD;
             ependymoma&#xD;
&#xD;
          -  Post-menarchal female not pregnant or nursing (breast feeding) and with a negative&#xD;
             beta-HCG pregnancy test prior to commencing the trial&#xD;
&#xD;
          -  Males and females of reproductive age and childbearing potential with effective&#xD;
             contraception for the duration of their treatment and 6 months after the completion of&#xD;
             their treatment&#xD;
&#xD;
          -  No contraindication to the use if one of the study drugs proposed by the protocol&#xD;
&#xD;
          -  Patients and/or their parents or legal guardians willing and able to comply with&#xD;
             scheduled visits, treatment plan, laboratory tests and other study procedure&#xD;
&#xD;
        Common inclusion criteria for Strata 1 and 2:&#xD;
&#xD;
          -  Age &gt; 12 months and &lt; 22 years at time of study entry&#xD;
&#xD;
          -  Histologically confirmed WHO Grade II-III ependymoma by central pathological review&#xD;
&#xD;
          -  No metastasis on spinal MRI and on CSF cytology assessments&#xD;
&#xD;
          -  No previous radiotherapy&#xD;
&#xD;
          -  No previous chemotherapy (except steroids)&#xD;
&#xD;
          -  No co-existent unrelated disease at the time of study entry that would render the&#xD;
             patient unable to receive chemotherapy&#xD;
&#xD;
          -  No medical contraindication to radiotherapy and chemotherapy&#xD;
&#xD;
          -  No signs of infection&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal functions&#xD;
&#xD;
        Specific inclusion criteria for Stratum 1:&#xD;
&#xD;
        • No residual measurable ependymoma based on the central neuroradiological review (R0-1-2)&#xD;
&#xD;
        Specific inclusion criteria for Stratum 2:&#xD;
&#xD;
        • Residual non reoperable measurable ependymoma based on the central neuroradiological&#xD;
        review (R3-4)&#xD;
&#xD;
        Inclusion criteria for Stratum 3:&#xD;
&#xD;
          -  Children younger than 12 months at time of entry to study or any children ineligible&#xD;
             to receive radiotherapy due to age at diagnosis, tumour location or clinician / parent&#xD;
             decision and according to national criteria&#xD;
&#xD;
          -  Histologically confirmed WHO Grade II-III ependymoma by central pathological review&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal functions&#xD;
&#xD;
          -  No previous chemotherapy and radiotherapy&#xD;
&#xD;
          -  No contraindication to chemotherapy&#xD;
&#xD;
          -  No co-existent unrelated disease at the time of study entry that would render the&#xD;
             patient unable to receive chemotherapy&#xD;
&#xD;
          -  No signs of infection. Patients that do not fulfill the inclusion criteria of one of&#xD;
             the interventional strata will be enrolled and followed up into an observational study&#xD;
             and descriptive analysis will be performed.&#xD;
&#xD;
        EXCLUSION CRITERIA for all interventional strata:&#xD;
&#xD;
          -  Tumour entity other than primary intracranial ependymoma&#xD;
&#xD;
          -  Primary diagnosis predating the opening of SIOP Ependymoma II&#xD;
&#xD;
          -  Patients with WHO grade I ependymoma including ependymoma variants: myxopapillary&#xD;
             ependymomas and subependymomas,patients with spinal cord location of the primary&#xD;
             tumour&#xD;
&#xD;
          -  Participation within a different trial for treatment of ependymoma&#xD;
&#xD;
          -  Contraindication to one of the IMP used according to the SmPCs&#xD;
&#xD;
          -  Concurrent treatment with any anti-tumour agents&#xD;
&#xD;
          -  Inability to tolerate chemotherapy&#xD;
&#xD;
          -  Unable to tolerate intravenous hydration&#xD;
&#xD;
          -  Pre-existing mucositis, peptic ulcer, inflammatory bowel disease ascites, or pleural&#xD;
             effusion.&#xD;
&#xD;
        Strata 1 and 2:&#xD;
&#xD;
          -  Ineligible to receive radiotherapy&#xD;
&#xD;
          -  Patient for whom imaging remains RX despite all effort to clarify the MRI conclusion&#xD;
&#xD;
        Stratum 3:&#xD;
&#xD;
          -  Pre-existing severe hepatic and/or renal damage&#xD;
&#xD;
          -  Family history of severe epilepsy&#xD;
&#xD;
          -  Presence of previously undiagnosed mitochondrial disorder detected by screening as&#xD;
             part of trial&#xD;
&#xD;
          -  Elevated blood ammonium and lactate level ≥ 1.5 x upper limit of the normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre LEBLOND, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IHOP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre LEBLOND, MD</last_name>
    <phone>+33 4 69 16 66 14</phone>
    <email>pierre.leblond@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz-Department of Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Benesch, MD</last_name>
      <phone>+43 (0) 316/385-80427</phone>
      <email>martin.benesch@klinikum-graz.at</email>
    </contact>
    <investigator>
      <last_name>Martin Benesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de la CITADELLE</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Piette</last_name>
      <phone>+32 4 225 60 97</phone>
      <email>caroline.piette@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Caroline Piette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Sterba, MD</last_name>
      <phone>+420 532 234 600/755</phone>
      <email>jsterb@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Sterba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille Wendtland Edslev</last_name>
      <phone>+45 78451701</phone>
      <email>pernedsl@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Pernille Wendtland Edslev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU STRASBOURG - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Entz-Werle, MD</last_name>
      <phone>+33 3 88 12 83 96</phone>
      <email>natacha.entz-werle@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Natacha Entz-Werle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hôpital d'Enfants de La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Gentet, MD</last_name>
      <phone>+33 4 91 38 68 21</phone>
      <email>jean-claude.gentet@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Gentet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hôpital des Enfants</name>
      <address>
        <city>Dijon</city>
        <state>Côte d'Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Briandet, MD</last_name>
      <phone>03 80 29 34 14</phone>
      <phone_ext>+33</phone_ext>
      <email>claire.briandet@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Briandet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU BESANCON - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Laithier, MD</last_name>
      <phone>+33 3 81 66 81 66</phone>
      <email>vlaithier@chu-besançon.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique Laithier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU BREST - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <state>Finistère</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liana-Stefania Carausu, MD</last_name>
      <phone>+33 2 98 22 33 81</phone>
      <email>liana.carausu@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Le Moine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liana-Stefania Carausu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux-Hôpital des enfants Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Icher, MD</last_name>
      <phone>+33 5 57 82 04 34</phone>
      <email>celine.icher@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Icher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Isabelle Bertozzi-Salamon, MD</last_name>
      <phone>+33 5 34 55 86 13</phone>
      <email>bertozzi.ai@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Isabelle Bertozzi-Salamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU MONTPELLIER - Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Sirvent, MD</last_name>
      <phone>+33 4 67 33 65 19</phone>
      <email>n-sirvent@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Sirvent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Palenzuela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Ile-De-France</state>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Doz, MD</last_name>
      <phone>+33 1 44 32 46 01</phone>
      <email>francois.doz@curie.fr</email>
    </contact>
    <investigator>
      <last_name>François Doz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa Guérrini-Rousseau, MD</last_name>
      <phone>+33 1 42 11 42 11</phone>
      <email>lea.guerrini-rousseau@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Léa Guérrini-Rousseau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charline Normand, MD</last_name>
      <phone>+33 2 99 26 58 35</phone>
      <email>charline.normand@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Chappe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours - Hôpital Clocheville</name>
      <address>
        <city>Tours</city>
        <state>Indre-et-Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Blouin, MD</last_name>
      <phone>02 47 47 49 72</phone>
      <phone_ext>+33</phone_ext>
      <email>p.blouin@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Blouin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU GRENOBLE - Hôpital Couple-Enfant</name>
      <address>
        <city>La Tronche</city>
        <state>Isère</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Pagnier, MD</last_name>
      <phone>+33 4 76 76 54 69</phone>
      <email>apagnier@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Pagnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <state>Loire</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Thouvenin, MD</last_name>
      <phone>04 77 82 88 08</phone>
      <phone_ext>+33</phone_ext>
      <email>sandrine.thouvenin@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine Thouvenin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie De Carli, MD</last_name>
      <phone>+33 2 41 35 38 63</phone>
      <email>EmDecarli@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie De Carli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU REIMS - American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Pluchart, MD</last_name>
      <email>cpluchart@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Claire Pluchart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Brabois Hôpital d'Enfants</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Chastagner, MD</last_name>
      <phone>+33 3 83 15 46 37</phone>
      <email>p.chastagner@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Ludovic Mansuy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Chastagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre OSCAR LAMBRET</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène SUDOUR, MD</last_name>
      <phone>+33 3 20 29 59 56</phone>
      <email>h-sudour@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène SUDOUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont- Ferrand - Hôpital Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy-de-Dôme</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Paillard, MD</last_name>
      <phone>+33 4 73 75 00 09</phone>
      <email>cpaillard@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Justyna Kanold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre LEON BERARD</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69473</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre LEBLOND, MD</last_name>
      <phone>+33 4 69 16 66 14</phone>
      <email>pierre.leblond@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Leblond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Schneider, MD</last_name>
      <phone>02 32 88 81 91</phone>
      <phone_ext>+33</phone_ext>
      <email>pascale.schneider@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU AMIENS-PICARDIE - Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Devoldere, MD</last_name>
      <phone>+33 3 22 66 89 50</phone>
      <email>devoldere.catherine@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Devoldere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU POITIERS - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <state>Vienne</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Millot, MD</last_name>
      <phone>+33 5 49 44 30 78</phone>
      <email>f.millot@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric Millot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Piguet, MD</last_name>
      <phone>+33 5 55 05 68 01</phone>
      <email>christophe.piguet@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Piguet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine SOLER, MD</last_name>
      <phone>+33492039268</phone>
      <email>soler.c@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves REGUERRE, MD</last_name>
      <email>Yves.reguerre@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Reguerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Rutkowski, MD</last_name>
      <email>s.rutkowski@uke.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Capra, MD</last_name>
      <phone>+353 1 409 6659</phone>
      <email>Michael.capra@olhsc.ie</email>
    </contact>
    <investigator>
      <last_name>Michael Capra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Massimino, MD</last_name>
      <phone>+39 0223902593</phone>
      <email>Maura.Massimino@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Maura Massimino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center for pediatric oncology</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasper van der Lugt, MD</last_name>
      <phone>+31 6 1855 96 94</phone>
      <email>J.vanderLugt@prinsesmaximacentrum.nl</email>
    </contact>
    <investigator>
      <last_name>Jasper van der Lugt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Paediatric, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Kristin Torsvik, MD, PhD</last_name>
      <phone>+47 5597 5199</phone>
      <email>Ingrid.kristin.torsvik@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Ingrid Kristin Torsvik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lidija Kitanovski, MD</last_name>
      <phone>+ 386 1 522 9215 / 522 9256</phone>
      <email>lidija.kitanovski@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Lidija Kitanovski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen Macarena y Virgen del Rocío Avda</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Fernández-Teijeiro, MD</last_name>
      <phone>+34677903132</phone>
      <email>anateijeiro@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Fernández-Teijeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Mörse, MD</last_name>
      <phone>+46 46 178281</phone>
      <email>Helena.Morse@skane.se</email>
    </contact>
    <investigator>
      <last_name>Helena Mörse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gerber, MD</last_name>
      <phone>+41 44 266 31 17</phone>
      <email>nicolas.gerber@kispi.uzh.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Gerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Grundy, MD</last_name>
      <phone>+44 115 8230620</phone>
      <email>richard.grundy@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Grundy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ependymoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

